Navigation Links
Old drug, new tricks: Prospects for slashing the impact of malaria

A dramatic reduction in the impact of malaria is in prospect with a clinical drug trial to begin in Papua New Guinea early next year. Success in the trial would open the way to relief in the 10% of humanity infected with this debilitating and often fatal disease - over 500,000,000 people.

The Walter and Eliza Hall Institute of Medical Research is collaborating with the Papua New Guinea Institute of Medical Research (PNGIMR) and the University of Melbourne to confirm significant health benefits in the new application of an old malaria drug - at just 12 cents a dose. The project is supported by a AUD$3. 7 million grant to PNGIMR from the Bill and Melinda Gates Foundation.

Fansidar is a 20-year-old malaria drug. As with many other such curative drugs, its effectiveness has declined over time with increased resistance by the malaria parasite. But initial clinical evidence suggests that Fansidar could have a new lease on life as a protective drug that strengthens a person's own immune system against malaria.

Early field experiments were conducted in the African country of Tanzania in the late 1990s. These suggested that giving just one Fansidar tablet to an apparently healthy child during their routine infant immunization visits dramatically reduced the impact of any subsequent malaria infection. Used in this way, Fansidar does not prevent malaria but seems to produce a massive 50% reduction in death, debilitation and complications of malaria, such as severe anaemia and raging fevers.

Joint project leader, Dr Louis Schofield from WEHI, says, "There seems to be a totally unexpected residual immunological effect when children are given this tablet as a preventative rather than as a post-infection treatment for malaria. While the drug itself dissipates in the bloodstream over a few days, it appears to enable the immune system to re-energize and more successfully combat any subsequent malarial infection. We suspect that many toddlers who se em reasonably healthy might actually have low level malarial infections that are eliminated by Fansidar, allowing the immune system to develop to its full potential."

WEHI's Dr James Beeson adds, "Most of the 2 million or so annual deaths from malaria and much of the severe illness involves children under five years of age. Pregnant women are also highly susceptible to the effects of malaria, but the good news is that they too appear to have much greater immune protection conferred by the preventative or 'presumptive' use of Fansidar. This looks like a case of teaching an old drug new tricks - or perhaps the old drug teaching us that it can perform tricks that we never suspected it could."

The four-year trial is being conducted in PNG for a number of reasons. First, PNG is a relatively confined area with a high concentration of all four types of global malaria ?unlike Africa, where one type predominates. Second, outstanding field researchers with clinical trial capability from the PNGIMR can collaborate with world leading Australian experts in malaria from WEHI and the University of Melbourne. Third, the organizational and public health infrastructure already exists to dispense the tablets in a controlled way, since PNG's children routinely attend clinics to be vaccinated against a range of other diseases.

The project funding allows significant expansion of joint activities and research among the collaborating institutions.

Successful completion of the trial is likely to help inform global health policy in combating this most serious disease of humanity.


Source:Research Australia

Related biology news :

1. Researchers reveal the infectious impact of salmon farms on wild salmon
2. Measuring the impact of post-genomics on Mediterranean populations
3. Second messenger NAADP shows fast, dose-related impact on satiety cycle
4. The first impact factor for PLoS Biology ?13.9
5. Open Access journals get impressive impact factors
6. OHSU research shows vitamin C counteracts some negative impacts of smoking on unborn babies
7. York scientists warn of dramatic impact of climate change on Africa
8. Breath of the dragon: ERS-2 and Envisat reveal impact of economic growth on Chinas air quality
9. Amazon trees much older than assumed, raising questions on global climate impact of region
10. Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful
11. Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice
Post Your Comments:

(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: ... Mr. Pierre Laurin , President and Chief Executive Officer ... upcoming Piper Jaffray 27 th Annual Healthcare Conference to ... 1-2, 2015. st , at 8.50am (ET) ... throughout the day. The presentation will be available live via ...
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/24/2015)... Nov. 24, 2015 According to two new studies, ... This is something that many doctors, scientists, and public health ... remains: with fewer PSA tests being done, will there be ... Dr. David Samadi, "Despite the efforts made in ... the second leading cancer cause of death in men, killing ...
Breaking Biology Technology: